Resistance Bacterial
14
2
3
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
7.1%
1 terminated out of 14 trials
88.9%
+2.4% vs benchmark
36%
5 trials in Phase 3/4
38%
3 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (14)
Use of the xCELLigence System for Quantification of Bacterial Biofilm's Real Time Formation and Antibiotics Selection.
Decreasing Irrational Antimicrobial Use in Bangladesh: A Digital Intervention Program
Azithromycin for Child Survival in Niger: Mortality and Resistance Trial
Azithromycin for Child Survival in Niger: Programmatic Trial (AVENIR)
T2Resistance - Detection of Resistance Related Genes
TB-CAPT MTB/XDR Study
Decolonization of Gram-negative Multi-resistant Organisms (MDRO) with Donor Microbiota (FMT)
Susceptibility Testing In Neisseria Gonorrhoeae (STING) Study, Assessing the Performance of a New Rapid Test for Gonorrhoea Antibiotic Resistance, in a Cohort of 100 Culture Positive Neisseria Gonorrhoeae Infections
Molecular Diagnostics of Bacterial Infections and Antibiotic Resistance in Blood Samples and Rectal Swabs Using Advanced NGS Sequencing Methods
MORDOR II Burkina Faso: Longitudinal Trial
Understanding and Modeling Reservoirs, Vehicles and Transmission of ESBL-producing Enterobacteriaceae in the Community and Long Term Care Facilities
Epidemiology and Determinants of Outcomes of Hospital Acquired Blood Stream Infections in the Intensive Care
Effectiveness of Rifabutin for Treatment of Helicobacter Pylori
Impact of Antimicrobial Stewardship Programs in the Global Setting